• Contributed to the integration of Glucose-Responsive-Insulin program into Merck following the acquisition of SmartCells. • Designed, synthesized and purified novel Insulin-Oligosaccharide-Conjugates (IOC’s) for biological testing. • Increased IOC production by identifying rate limiting step and providing a solution. • Initiated inventory and tracking of program intermediates ensuring uninterrupted workflow.• Research and development support for Rahway/Kenilworth lead optimization programs in cardiovascular, diabetes and urology therapeutic areas. • Co-inventor Vibregon a Beta 3 receptor agonist currently in phase 3 clinical trials.• Provided scientific supervision to associate level scientist.• Represented Merck Discovery Chemistry at external scientific meeting.• Responsible for implementing and managing safety directives as part of chemistry safety team.

• Responsible for the design, synthesis, purification and characterization of novel chemical entities for biological evaluation against a range of therapeutic targets in the neuroscience field. • Co-inventor MK-812 a CCR2 receptor antagonist progressed to phase 2 clinical trials.• Provided scientific supervision for an associate level scientist and medicinal chemistry intern.• Completed a 1 year rotation in the Rahway (US) medicinal chemistry department.• Presented data at departmental meetings.

• Independently designed and synthesized novel molecular entities for biological evaluation against a range of therapeutic targets in the neuroscience field.• Represented Terlings Park chemistry department at external meeting.• Managed the on-site hydrogenation facility.• Assisted in the recruitment of associate level scientists.• Presented work at departmental meetings.

• Independently designed and synthesized novel molecular entities for biological evaluation against a range of therapeutic targets in the neuroscience field.• Followed structure activity relationships to aid in the design of novel molecular analogs for syntheses.• Provided guidance to junior members of the team.• Presented work at departmental meetings.

• Synthesized new molecular entities for biological evaluation• Followed structure activity relationships to aid in the design of novel molecular analogs for syntheses.• Presented work at departmental meetings.• Presented data at group meetings.

• Synthesized new molecular entities for biological evaluation.• Collated data and prepared reports for supervisor and management.• Presented data at group meetings.